Article Information
History
- March 18, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Filip Mjörnstedt1,
- Rebecka Wilhelmsson, M. Sc.1,
- Marcus Ulleryd, PhD1,
- Maria Hammarlund, PhD1,
- Göran Bergström, MD, PhD2,3,
- Anders Gummesson, MD, PhD2,4 and
- Maria E Johansson, PhD.1,*
- 1Department of Physiology, Institute of Neuroscience and Physiology, Gothenburg University, Gothenburg, Sweden
- 2Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden
- 3Department of Clinical Physiology, Sahlgrenska University Hospital, Västra Götalandsregionen, Gothenburg, Sweden
- 4Department of Clinical Genetics and Genomics, Sahlgrenska University Hospital, Västra Götalandsregionen, Gothenburg, Sweden
- ↵*Correspondence
Maria E. Johansson, maria.e.johansson{at}neuro.gu.se, Department of Physiology, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Box 432, Gothenburg 405 30, Sweden
Posted March 18, 2024.
Alpha7 nicotinic acetylcholine receptor agonist PHA 568487 dampens inflammation in PBMCs from patients with newly discovered coronary artery disease
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos